patent.fyi
Applications  /  US 2026/0356820
United States Patent Application Publication

US 2026/0356820 A1

Published
Nov 12, 2026
Filed
Oct 3, 2023
Earliest date on the face
Oct 3, 2022
Classification
C07D 403/06
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Silicon at the U position

What ifWhat if a dimethylsilylene unit occupies the U position?
Claim language“U represents CH2, O, S, or NRU”

A silicon atom bearing two methyl groups forms single bonds to the two neighboring scaffold atoms. The silicon unit preserves the connection between those atoms and increases their separation relative to a methylene bridge.

1.5Direct boronic acid substitution

What ifWhat if an aromatic R1 position bears a boronic acid group through a direct carbon–boron bond?
Claim language“C3-8 cycloalkyl, nitrile, NRXRY, and combinations thereof”

The ring carbon bonds directly to the boron atom of B(OH)2. The two hydroxyl groups provide hydrogen-bonding sites at the ring perimeter.

1.6Eight-membered fused ring

What ifWhat if the two adjacent substitution sites form an eight-membered ring?
Claim language“a 5- to 7-membered saturated or unsaturated ring”

A —O—(CH2)4—O— bridge joins the two adjacent ring carbons. The six bridge atoms and the two shared carbons form an eight-membered ring that constrains the relative positions of the two substituents.

1.7Sulfonyl at the Z position

What ifWhat if a sulfonyl unit occupies the Z position?
Claim language“Z represents CRZRZ′, C═S, or C═O”

The sulfur atom forms a single bond to each neighboring scaffold atom and bears two terminal oxo groups. The resulting unit retains the two scaffold connections and presents two hydrogen-bond acceptors.

1.8Divalent sulfur at X

What ifWhat if a divalent sulfur atom occupies the X position?
Claim language“X represents C(R15)(R16), N(R17) or O”

Sulfur forms a single bond to each neighboring scaffold atom and creates a thioether linkage. The two carbon–sulfur bonds give the linkage a greater bond length than the corresponding ether.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Specific version of a part

Fluorinated carbon at W

W is C(R4), with fluorine as R4. The carbon retains its two ring connections and carries a single carbon–fluorine bond.

Ring nitrogen at Y

Y is a pyridine-type ring nitrogen. Its lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.

Hydroxymethyl substituent at X

X is C(R15)(R16), with hydroxymethyl as R15 and hydrogen as R16. A single methylene group connects the X carbon to the terminal hydroxyl.

Spirocyclobutane at the X carbon

R15 and R16 together form a —CH2—CH2—CH2— bridge with both ends bonded to the X carbon. The bridge and the X carbon form a cyclobutane that shares the X carbon with the scaffold ring.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 11,136,324 B2
Published
Oct 5, 2021
Filed
Mar 2, 2018
Class
C07D 487/04
Document BUS 2022/0144829 A1
Published
May 12, 2022
Filed
Oct 18, 2021
Class
C07D 471/04
Claim 1
Document A
Document B
1.1U represents CH2, O, S, or NRU
1.2W represents C(R4) or N
1.3Y represents C(R6) or N
1.4Q represents O or S
1.5R1, R2, R3, R4, R6, R7, R8, R9, and R10 independently represent hydrogen, deuterium, C1-6 alkyl, C2-6 alkenyl, alkynyl, hydroxy, thiol, C1-6 alkoxy, halogen, haloC1-6 alkyl, haloC1-6 alkoxy, C3-8 cycloalkyl, nitrile, NRXRY, and combinations thereof
Ra is selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CR9R10)n—, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(O)OR9, —(CH2)nS(O)mR9, —(CH2)nNR10R11, —(CH2)nC(O)NR10R11, —(CH2)nC(O)NHR10, —(CH2)nNR10C(O)R9 and —(CH2)nNR10S(O)mR9, wherein the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl
A · US 11,136,324 B2 · ¶ 41
each R6 is independently hydrogen, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, or 3- to 6-membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C14 aryl, 5- to 10-membered heteroaryl, and 3- to 6-membered heterocyclyl of R6 are independently optionally substituted by deuterium, halogen, oxo, —CN, —OR10, —NR11R12, or C1-C6 alkyl optionally substituted by deuteriu
B · US 2022/0144829 A1 · ¶ 87
1.6wherein two adjacent groups R1 to R4 or R6 to R10 optionally join to form a 5- to 7-membered saturated or unsaturated ring optionally containing one or more heteroatoms selected from O, N or S
or, any two Ra on ring B can form a new cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the newly formed cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CR9R10)n—, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(
A · US 11,136,324 B2 · ¶ 42
In some variations, Z is taken together with the adjacent “NR” group to form a heterocyclic ring.
B · US 2022/0144829 A1 · ¶
1.7R5 and RU independently represent hydrogen, deuterium, C1-6 alkyl, C2-6 alkenyl, alkynyl, hydroxy, thiol, C1-6 alkoxy, halogen, haloC1-6 alkyl, haloC1-6 alkoxy, C3-8 cycloalkyl, nitrile, —NRXRY, aryl, heteroaryl, heterocyclyl, amide, and combinations thereof, Z represents CRZRZ′, C═S, or C═O
R5 is halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, —(CH2)nC(O)R12, —(CH2)nC(O)NR12R13, —(CH2)nC(O)OR12, —(CH2)nNR12R13, —(CH2)nNR13C(O)R12, —(CH2)nNR13S(O)mR12, —(CH2)nOR12, —(CH2)nS(O)mR12, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R6 is independently hydrogen, deuterium, halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, —(CH2)nC(O)R9, —(CH2)nC(O)NR10R11, —(CH2)nC(O)OR9, —(CH2)nNR10R11, —(CH2)nNR10C(O)R9, —(CH2)nNR10S(O)mR9, —(C
A · US 11,136,324 B2 · claim 1
R2 is C1-C6 alkyl optionally substituted by R2a, C3-C5 cycloalkyl optionally substituted by R2b, 3- to 12-membered heterocyclyl optionally substituted by R2c, C6-C14 aryl optionally substituted by R2d, 5- to 10-membered heteroaryl optionally substituted by R2e, —OR2f, or —NR2gR2h;
B · US 2022/0144829 A1 · claim 1
1.8X represents C(R15)(R16), N(R17) or O
1.9R15, R16, and R17 independently represent hydrogen, deuterium, C1-6 alkyl, haloC1-6 alkyl, —OR15a, —SR15a, nitrile, —COC1-6 alkyl, —COOC1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanol, C3-8 cycloalkyl, halogen, carbonyl, —NRVRW, —CH2—NRVRW, —OSO2NH2, —P(O)OH2, aryl, heteroaryl, heterocyclyl, and combinations thereof
R12 and R13 are identical or different and are each independently selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, hydroxy, amino, ester group, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, halogen, hydroxy, amino, nitro, cyano, ester group, al
A · US 11,136,324 B2 · ¶ 24
1.10wherein R15, R16, and R17 may further comprise one or more divalent linkers L selected from the group consisting alkylene, cycloalkylene, heteroalkylene, heterocycloalkylene, alkenylene, alkynylene, arylene, heteroarylene, silyl, amine, amide, ester, ether, carbonyl, carbamate, sulfamate, sulfonic ester, sulfoximine, sulfonamide, thioether, thioester, disulfide, hydrazine, urea, thiourea, phosphate, phosphonate ester, poly(alkyl ether), heteroatom, and combinations thereof
1.11wherein R15 and R16 may be taken together to form a ring
The above substituents can be bonded to different carbon atoms to form a carbon chain, or can be bonded to one carbon atom to form a cycloalkyl.
A · US 11,136,324 B2 · ¶ 134
1.12n is 0, 1, or 2 wherein when n is 0, N is directly bonded to the carbon having RB and RB′ bound thereto each RA, RA′, RZ, and RZ′ independently represents hydrogen, deuterium, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanol, halogen, —OR15b, CO2H, CO2R15b, haloC1-6 alkyl, and combinations thereof, RB and RB′ independently represents hydrogen, deuterium, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanol, halogen, —OR15b, CO2H, CO2R15b, haloC1-6 alkyl, and combinations thereof, or RB and the carbon to which it is bound together form a carbonyl group and RB′ is not present R15a and R15b independently represent hydrogen, deuterium, or C1-6 alkyl wherein two groups R15a and R15b, or two groups R15b, may join together to form a 5 to 7 membered saturated ring system which may be optionally substituted by one or more C1-6 alkyl groups RV, RW, RX and RY independently represent hydrogen, deuterium, C1-6 alkyl, haloC1-6 alkyl, C3-8 cycloalkyl, —COC1-6 alkyl or heterocyclyl wherein said alkyl groups may be optionally substituted with or more deuterium, hydroxy, amino or sulfone groups said heterocyclyl ring may be optionally substituted by one or more deuterium, oxo, hydroxy, C1-6 alkanol or —COC1-6 alkyl groups.
R2g and R2h are each independently hydrogen, deuterium, C1-C6 alkyl, C3-C5 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C5 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of R2g and R2h are independently optionally substituted by R2j; each R2a, R2b, R2c, R2d, R2e, R2i, R2j, R3a, R3b, R3c, R3d, R3′ and Ya is independently ═O or R4; each R4 is independently deuteri
B · US 2022/0144829 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
At present, there are no drugs approved for treating NASH.
A · US 11,136,324 B2 · ¶ 5
ASK1 inhibitors have great potential for the clinical treatment of NASH, and have potential valuable application in the treatment of other diseases including neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune metabolic diseases and the like.
A · US 11,136,324 B2 · ¶ 5
The therapeutic agents may be used in the treatment or prophylactic treatment of fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
B · US 2022/0144829 A1 · ¶ 2
If left untreated, fibrosis can result in scarring of vital organs causing irreparable damage and eventual organ failure.
B · US 2022/0144829 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0356820 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356820/, SHA-256 57f250e3802570c81bff793d906382130db9ce6e66bcbc3d9f51aea62958f2e1
First published
Permanent addresshttps://patent.fyi/US20260356820/
Content fingerprint (SHA-256)57f250e3802570c81bff793d906382130db9ce6e66bcbc3d9f51aea62958f2e1
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi